Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit
WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced Randi Isaacs, M.D., Chief Medical Officer, will speak at the upcoming KidneyCAN 7th Annual Kidney Cancer Research Summit taking place July 17-18 in Boston, Massachusetts.
The presentation will focus on Werewolf’s innovative approach to harnessing conditionally-activated cytokines designed to selectively activate immune responses within tumors. It will cover early clinical findings from the development of WTX-124, a tumor-activated IL-2 INDUKINE molecule. While high-dose IL-2 is a proven therapy for renal cell carcinoma (RCC), among other solid tumors, its use is limited by severe toxicity. Dr. Isaacs will highlight how the WTX-124 strategy aims to improve the therapeutic index, maximizing anti-tumor activity in immunotherapy-sensitive tumors like RCC while reducing systemic side effects. Presentation details:
Session:8 – Biotech Showcase
Title: Unmasking the Potential of Conditionally-Activated Cytokines: Lessons Learned from the Early Clinical Development of WTX-124, a Tumor-Activated IL-2 INDUKINE Molecule
Date: Friday, July 18, 2025
Time: 2:45pm ET
Werewolf continues to conduct the “Full Moon Moment,” an awareness campaign supporting its ongoing national trials, including the WTX-124 IL-2 INDUKINE molecule, which is actively enrolling patients with advanced or metastatic RCC, among other solid tumors. Multiple responses have been reported, including a patient with cutaneous squamous cell carcinoma who has been in remission for more than a year. The campaign highlights the potential for such outcomes and encourages patients to explore new options. “Full Moon Moment” represents how INDUKINE™ molecules activate their tumor-killing power within the tumor microenvironment. Learn more about Werewolf’s current WTX-124 clinical trial here.
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Werewolf’s strategy, future operations, prospects, plans, and objectives of management; the potential activity and efficacy of product candidates in preclinical studies and clinical trials; and the anticipated safety profile of product candidates constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “design,” “designed to,” “engineered,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “positioning itself to,” “potential,” “predict,” “project,” “promise,” “should,” “target,” “will,” “working to,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the development of product candidates, including the conduct of research activities, and the initiation and completion of preclinical studies and clinical trials; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; whether preliminary or interim data from a clinical trial will be predictive of the future results of the trial and future clinical trials; as well as the risks and uncertainties identified in the “Risk Factors” section of the Company’s most recent Form 10-Q filed with the Securities and Exchange Commission (SEC), and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.
Investor Contact
Dan Ferry
LifeSci Advisors
617.430.7576
daniel@lifesciadvisors.com
Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com
Company Contact:
Timothy Trost
Chief Financial Officer
Werewolf Therapeutics
ttrost@werewolftx.com
© 2025 GlobeNewswire, Inc. All Rights Reserved.
